EA201490756A1 - Разагилина цитрамид - Google Patents

Разагилина цитрамид

Info

Publication number
EA201490756A1
EA201490756A1 EA201490756A EA201490756A EA201490756A1 EA 201490756 A1 EA201490756 A1 EA 201490756A1 EA 201490756 A EA201490756 A EA 201490756A EA 201490756 A EA201490756 A EA 201490756A EA 201490756 A1 EA201490756 A1 EA 201490756A1
Authority
EA
Eurasian Patent Office
Prior art keywords
rasagiline
citramide
razaglinina
citramid
salt
Prior art date
Application number
EA201490756A
Other languages
English (en)
Inventor
Константин Уланенко
Грегори Верба
Мухаммад Сафади
Антон Френкел
Михал Кейсар
Данит Лихт
Элизер Бахар
Рами Лидор-Хадас
Марина Жолковски
Рахель Коэн
Original Assignee
Тева Фармасьютикал Индастриз, Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тева Фармасьютикал Индастриз, Лтд. filed Critical Тева Фармасьютикал Индастриз, Лтд.
Publication of EA201490756A1 publication Critical patent/EA201490756A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/14—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение предлагает разагилина цитрамид и способ получения разагилина цитрамида из разагилина. Также предлагает композиции, содержащие пропаргил-1(R)-аминоиндан или его фармацевтически приемлемую соль и соединение разагилина цитрамид или его соль, и способы утверждения указанной фармацевтической композиции, основанные на процентном содержании разагилина цитрамида относительно разагилина.
EA201490756A 2011-10-10 2012-10-09 Разагилина цитрамид EA201490756A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161545414P 2011-10-10 2011-10-10
PCT/US2012/059353 WO2013055684A1 (en) 2011-10-10 2012-10-09 Rasagiline citramide

Publications (1)

Publication Number Publication Date
EA201490756A1 true EA201490756A1 (ru) 2014-09-30

Family

ID=48042234

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201490756A EA201490756A1 (ru) 2011-10-10 2012-10-09 Разагилина цитрамид

Country Status (14)

Country Link
US (1) US20130089611A1 (ru)
EP (1) EP2766007A4 (ru)
JP (1) JP2014534195A (ru)
KR (1) KR20140074388A (ru)
CN (1) CN103857389A (ru)
AR (1) AR088296A1 (ru)
AU (1) AU2012323346A1 (ru)
BR (1) BR112014008550A2 (ru)
CA (1) CA2851274A1 (ru)
EA (1) EA201490756A1 (ru)
HK (1) HK1200313A1 (ru)
IL (1) IL231720A0 (ru)
MX (1) MX2014004196A (ru)
WO (1) WO2013055684A1 (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007098264A2 (en) * 2006-02-21 2007-08-30 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
WO2007117431A2 (en) * 2006-04-03 2007-10-18 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of restless legs syndrome
MX2009006251A (es) * 2006-12-14 2009-10-12 Teva Pharma Base de rasagilina solida cristalina.
NZ586025A (en) * 2008-01-11 2012-08-31 Teva Pharma Rasagiline mesylate tablet coated with a composisiton comprising methacrylic acid - ethyl acrylate copolymer and triethyl citrate
CA2727019A1 (en) * 2008-06-10 2009-12-17 Teva Pharmaceutical Industries Ltd. Rasagiline soft gelatin capsules
PL2451771T3 (pl) 2009-07-09 2014-12-31 Ratiopharm Gmbh Sole rasagiliny i ich preparaty farmaceutyczne
JP2013507352A (ja) * 2009-10-09 2013-03-04 テバ ファーマシューティカル インダストリーズ リミティド 進行性核上性麻痺の治療のためのラサギリンの使用
AU2010341499A1 (en) * 2009-12-22 2012-08-09 Teva Pharmaceutical Industries Ltd. 3-keto-N-propargyl-1-aminoindan
US8691872B2 (en) 2010-07-27 2014-04-08 Teva Pharmaceutical Industries Ltd. Dispersions of rasagiline citrate
KR20140084153A (ko) 2011-10-10 2014-07-04 테바 파마슈티컬 인더스트리즈 리미티드 R(+)-n-메틸-프로파길-아미노인단
BR112014008555A2 (pt) 2011-10-10 2017-04-18 Teva Pharma r(+)-n-formil-propargil-aminoindano
EP2884972A4 (en) 2012-08-17 2016-05-11 Teva Pharma PARENTERAL FORMULATION OF RASAGILINE
KR20210030632A (ko) 2019-09-10 2021-03-18 삼성중공업 주식회사 Lng 연료탱크 메인티넌스 전용 부유식 해상 구조물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2628432B1 (fr) * 1988-03-08 1990-12-21 Sanofi Sa Polymeres d'acide citrique et de diamines, leur procede de preparation et leurs applications notament comme vecteurs de medicaments
US5914349A (en) * 1994-01-10 1999-06-22 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
IL115357A (en) * 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
NZ589445A (en) * 2008-06-13 2013-06-28 Teva Pharma Rasagiline for parkinson's disease modification
US20100189790A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation

Also Published As

Publication number Publication date
CA2851274A1 (en) 2013-04-18
WO2013055684A8 (en) 2014-04-10
EP2766007A1 (en) 2014-08-20
AU2012323346A1 (en) 2014-05-15
HK1200313A1 (en) 2015-08-07
BR112014008550A2 (pt) 2017-04-18
CN103857389A (zh) 2014-06-11
KR20140074388A (ko) 2014-06-17
MX2014004196A (es) 2014-05-28
US20130089611A1 (en) 2013-04-11
AR088296A1 (es) 2014-05-21
IL231720A0 (en) 2014-05-28
EP2766007A4 (en) 2015-03-25
WO2013055684A1 (en) 2013-04-18
JP2014534195A (ja) 2014-12-18

Similar Documents

Publication Publication Date Title
EA201490756A1 (ru) Разагилина цитрамид
MD20150091A2 (ru) Противовирусные соединения
EA201491362A1 (ru) Анестезирующие соединения и способы их применения
MD20140136A2 (ru) Ингибиторы вируса гепатита С
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
EA201890899A1 (ru) Модуляторы фарнезоидного x-рецептора
EA201400412A1 (ru) ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
EA201171151A1 (ru) Кристаллические трипептидные ингибиторы эпоксикетон-протеазы
EA201492223A1 (ru) Новые диазаспироциклоалканы и азаспироциклоалканы
EA201490161A1 (ru) Соединения - ингибиторы сигналинга, опосредуемого рецептором notch
EA201590887A1 (ru) Композиция
EA201390880A1 (ru) Имидазопиридины в качестве противовирусных средств против респираторно-синцитиального вируса
EA201490567A1 (ru) Новые бициклические производные дигидрохинолин-2-она
EA201492287A1 (ru) Дейтерированные производные руксолитиниба
EA201290772A1 (ru) Новые формы ивабрадина гидрохлорида
EA201301240A1 (ru) Полиморфная форма бензоата линаглиптина
CA2830549C (en) Methods and compositions for preparing noribogaine from voacangine
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
EA201490850A1 (ru) Состав антитела, пригодный для профилактики и лечения амилоидоза, его варианты и способ его получения
EA201490846A1 (ru) Новые производные арилхинолина
EA200971140A1 (ru) Триарильные соединения и композиции, их содержащие
EA201791896A1 (ru) Дезацетокситубулизин н и его аналоги
WO2013080217A3 (en) Crystalline forms of carbazitaxel and process for preparation thereof
EA201491195A1 (ru) Способ получения композиции, содержащей галактоолигосахариды
EA201490760A1 (ru) R(+)-n-метилпропаргиламиноиндан